MRTX - Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings | Benzinga
Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy.
Clear cell renal cancer is the most common type of kidney cancer, comprising 80% of all malignant tumors found within the kidney.
The subcutaneous formulation of Opdivo used Halozyme Therapeutics Inc.'s (NASDAQ: HALO) recombinant human hyaluronidase.
The 495-patient study met its co-primary pharmacokinetics endpoints and key ...